Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
BioLineRx Entered Exclusive License Agreement to Motixafortide in Asia, Advised by MSQ Ventures 2023-10-31 21:00
BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures 2022-06-29 20:00
BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants 2019-02-08 02:42
BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants 2019-02-06 00:40
BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants 2019-02-05 06:54
1